[1]
|
Nalysnyk, L., Rotella, P., Simeone, J.C., Hamed, A. and Weinreb, N. (2016) Gaucher Disease Epidemiology and Natural History: A Comprehensive Review of the Literature. Hematology, 22, 65-73. https://doi.org/10.1080/10245332.2016.1240391
|
[2]
|
Zion, Y.C., Pappadopulos, E., Wajnrajch, M., et al. (2016) Re-Thinking Fatigue in Gaucher Disease. Orphanet Journal of Rare Diseases, 29, 1-7.
|
[3]
|
Rosenbloom, B.E. and Weinreb, N.J. (2013) Gaucher Disease: A Comprehensive Review. Critical Reviews in Oncogenesis, 18, 163-175. https://doi.org/10.1615/critrevoncog.2013006060
|
[4]
|
Lo, S.M., Stein, P., Mullaly, S., Bar, M., Jain, D., Pastores, G.M., et al. (2010) Expanding Spectrum of the Association between Type 1 Gaucher Disease and Cancers: A Series of Patients with up to 3 Sequential Cancers of Multiple Types—Correlation with Genotype and Phenotype. American Journal of Hematology, 85, 340-345. https://doi.org/10.1002/ajh.21684
|
[5]
|
Thomas, A.S., Mehta, A.B. and Hughes, D.A. (2013) Diagnosing Gaucher Disease: An On-Going Need for Increased Awareness amongst Haematologists. Blood Cells, Molecules, and Diseases, 50, 212-217. https://doi.org/10.1016/j.bcmd.2012.11.004
|
[6]
|
中国成人戈谢病诊治专家共识(2020) [J]. 中华医学杂志, 2020, 100(24): 1841-1849.
|
[7]
|
Revel‐Vilk, S., Szer, J., Mehta, A. and Zimran, A. (2018) How We Manage Gaucher Disease in the Era of Choices. British Journal of Haematology, 182, 467-480. https://doi.org/10.1111/bjh.15402
|
[8]
|
中华医学会儿科学分会遗传代谢内分泌学组, 中华医学会儿科学分会血液学组, 中华医学会血液学分会红细胞疾病(贫血)学组. 中国戈谢病诊治专家共识(2015) [J]. 中华儿科杂志, 2015, 53(4): 256‐261.
|
[9]
|
El-Beshlawy, A., Tylki-Szymanska, A., Vellodi, A., Belmatoug, N., Grabowski, G.A., Kolodny, E.H., et al. (2017) Long-term Hematological, Visceral, and Growth Outcomes in Children with Gaucher Disease Type 3 Treated with Imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 120, 47-56. https://doi.org/10.1016/j.ymgme.2016.12.001
|
[10]
|
Hobbs, J.R., Shaw, P.J., Jones, K.H., Lindsay, I. and Hancock, M. (1987) Beneficial Effect of Pre-Transplant Splenectomy on Displacement Bone Marrow Transplantation for Gaucher’s Syndrome. The Lancet, 329, 1111-1115. https://doi.org/10.1016/s0140-6736(87)91673-4
|
[11]
|
韩冰, 陈苗, 杨辰. 戈谢病多学科诊疗专家共识(2020) [J]. 协和医学杂志, 2020, 11(6): 682-697.
|
[12]
|
Orenstein, M., Barbouth, D., Bodamer, O.A. and Weinreb, N.J. (2014) Patients with Type 1 Gaucher Disease in South Florida, USA: Demographics, Genotypes, Disease Severity and Treatment Outcomes. Orphanet Journal of Rare Diseases, 9, Article No. 45. https://doi.org/10.1186/1750-1172-9-45
|
[13]
|
Essabar, L., Meskini, T., Lamalmi, N., Ettair, S., Erreimi, N. and Mouane, N. (2015) Gaucher’s Disease: Report of 11 Cases with Review of Literature. Pan African Medical Journal, 20, Article No. 18. https://doi.org/10.11604/pamj.2015.20.18.4112
|
[14]
|
张博健, 乔海泉. 戈谢病的外科研究进展[J]. 腹部外科, 2019, 32(2): 144-147.
|
[15]
|
Motta, I., Filocamo, M., Poggiali, E., Stroppiano, M., Dragani, A., Consonni, D., et al. (2015) A Multicentre Observational Study for Early Diagnosis of Gaucher Disease in Patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 96, 352-359. https://doi.org/10.1111/ejh.12596
|
[16]
|
Zimmermann, A., Popp, R.A., Al-Khzouz, C., Bucerzan, S., Naşcu, I., Leucuta, D., et al. (2016) Cholelithiasis in Patients with Gaucher Disease Type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. Journal of Gastrointestinal and Liver Diseases, 25, 447-455. https://doi.org/10.15403/jgld.2014.1121.254.zim
|
[17]
|
Zimran, A., Brill-Almon, E., Chertkoff, R., Petakov, M., Blanco-Favela, F., Muñoz, E.T., et al. (2011) Pivotal Trial with Plant Cell-Expressed Recombinant Glucocerebrosidase, Taliglucerase Alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease. Blood, 118, 5767-5773. https://doi.org/10.1182/blood-2011-07-366955
|
[18]
|
Weinreb, N., Taylor, J., Cox, T., Yee, J. and vom Dahl, S. (2008) A Benchmark Analysis of the Achievement of Therapeutic Goals for Type 1 Gaucher Disease Patients Treated with Imiglucerase. American Journal of Hematology, 83, 890-895. https://doi.org/10.1002/ajh.21280
|
[19]
|
Gary, S.E., Ryan, E., Steward, A.M. and Sidransky, E. (2018) Recent Advances in the Diagnosis and Management of Gaucher Disease. Expert Review of Endocrinology & Metabolism, 13, 107-118. https://doi.org/10.1080/17446651.2018.1445524
|
[20]
|
Giraldo, P., Andrade-Campos, M., Alfonso, P., Irun, P., Atutxa, K., Acedo, A., et al. (2018) Twelve Years of Experience with Miglustat in the Treatment of Type 1 Gaucher Disease: The Spanish ZAGAL Project. Blood Cells, Molecules, and Diseases, 68, 173-179. https://doi.org/10.1016/j.bcmd.2016.10.017
|
[21]
|
Hollak, C.E.M., Hughes, D., van Schaik, I.N., Schwierin, B. and Bembi, B. (2009) Miglustat (Zavesca®) in Type 1 Gaucher Disease: 5‐Year Results of a Post‐Authorisation Safety Surveillance Programme. Pharmacoepidemiology and Drug Safety, 18, 770-777. https://doi.org/10.1002/pds.1779
|